GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: AB-154 | AB154
Compound class:
Antibody
Comment: Domvanalimab (AB154) is an anti-TIGIT monoclonal antibody. It is designed to be 'Fc-silent' as a method to prevent depletiion of regulatory T cells (which would otherwise be promoted by Fc-mediated antibody dependent cellular cytotoxicity). Silencing TIGIT has two functions. It negates the inhibitory action of TIGIT binding to poliovirus receptor (PVR, CD155) which blocks immune suppression, and it leaves PVR available to interact with the costimulatory DNAM-1 (CD226) molecule. The combined effects potentiate a natural killer (NK) cell and T cell-mediated anti-tumour immune response.
|
| No information available. |
Summary of Clinical Use  |
| Domvanalimab is intended to be used in conjunction with anti-PD-1 checkpoint inhibitors to induce a two-armed activation of anti-tumour immunity [3]. This mechanism is being tested for safety and efficacy in advanced solid tumour types. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05502237 | Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer | Phase 3 Interventional | Gilead Sciences | 3 | |
| NCT05724563 | Domvanalimab and Zimberelimab in Advanced Liver Cancers | Phase 2 Interventional | University of Texas Southwestern Medical Center | 2 | |
